Loss of Sirtuin 7 impairs cell motility and proliferation and enhances S-phase cell arrest after 5-fluorouracil treatment in head and neck cancer - UTU Research Portal

A1 Refereed original research article in a scientific journal

Loss of Sirtuin 7 impairs cell motility and proliferation and enhances S-phase cell arrest after 5-fluorouracil treatment in head and neck cancer

Authors: Halasa, Marta; Afshan, Syeda; Wawruszak, Anna; Borkowska, Agata; Brodaczewska, Klaudia; Przybyszewska-Podstawka, Alicja; Kalafut, Joanna; Baran, Marzena; Rivero-Müller, Adolfo; Stepulak, Andrzej; Nees, Matthias

Publisher: Springer Science and Business Media LLC

Publication year: 2025

Journal: Scientific Reports

Journal name in source: Scientific Reports

Article number: 2123

Volume: 15

eISSN: 2045-2322

DOI: https://doi.org/10.1038/s41598-024-83349-9

Web address : https://doi.org/10.1038/s41598-024-83349-9

Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/484522612

Abstract

Sirtuin 7 (SIRT7), a member of the sirtuin family of NAD+-dependent deacetylases, plays a vital role in cancer, exhibiting context-dependent functions across various malignancies. Our study investigates the role of SIRT7 depletion in head and neck squamous cell carcinoma (HNSCC) progression. In vitro and 3D organotypic models demonstrated that SIRT7 knock-out attenuates cancer cell viability, proliferation, and motility as well as induces downregulation of migration- and epithelial-mesenchymal transition (EMT)-related gene expression. Moreover, the SIRT7 loss results in slower organoid formation and less invasive organoid morphology, validated by vimentin downregulation. The SIRT7 loss potentiates S-phase arrest in cell cycle progression after 5-FU treatment and elevates the ratio of dead cells. Additionally, SIRT7 deletion reduces the expression of G1 phase-associated proteins, Cyclin D and CDK4. Altogether, our study highlights SIRT7 as a promising therapeutic target in HNSCC, enhancing the effectiveness of treatment modalities such as combinational treatment.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

s41598-024-83349-9.pdf

Funding information in the publication:
The Polish National Agency for Academic Exchange, Poland, grant number PPN/IWA/2019/1/00160 and PPI/APM/2019/1/00089/U/00001 (M.H, A.S, M.N); the Polish National Science Centre (NCN) grant DEC-2017/25/B/NZ4/02364 (ARM); Jane and Aatos Erkko foundation, grant number 2600514111 (S.A, M.N); Turku University Foundation/Turun Yliopistosäätiö (080956, S.A.); Drug Research Doctoral Program, University of Turku (S.A); the Finnish-Norwegian Medical Foundation/ Suomalais- Norjalainen Lääketieteen Säätiö (2024043, S.A.); Ida Montinin Säätiö, Finland (20240522,S.A).